Zim Laboratories Ltd's Q4FY25 Quarter Results
- 21 May 2025
Result Summary
- Zim Laboratories Ltd reported a 21.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 12.5%.
- Its expenses for the quarter were up by 17.4% QoQ and 12.7% YoY.
- The net profit increased 102.3% QoQ and increased 11.7% YoY.
- The earnings per share (EPS) of Zim Laboratories Ltd stood at 1.7 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 119.40 | 98.08 | 106.10 | 21.7% | 12.5% |
Total Expenses | 108.41 | 92.38 | 96.16 | 17.4% | 12.7% |
Profit Before Tax | 11.00 | 5.70 | 9.94 | 93.0% | 10.7% |
Tax | 2.91 | 1.70 | 2.71 | 71.2% | 7.4% |
Profit After Tax | 8.09 | 4.00 | 7.24 | 102.3% | 11.7% |
Earnings Per Share | 1.70 | 0.80 | 1.50 | 112.5% | 13.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Zim Laboratories Ltd is a company that operates in the pharmaceutical industry, focusing on the development and manufacturing of drug delivery solutions. The company specializes in offering various pharmaceutical products, including oral dosage forms and novel drug delivery systems. These products are designed to improve patient compliance and therapeutic efficacy. As of the data up to October 2023, there are no specific recent major developments or strategic announcements available for Zim Laboratories Ltd. The company continues to engage in the pharmaceutical sector, contributing to the healthcare industry with its specialized offerings.
Revenue
In the fourth quarter of fiscal year 2025 (Q4FY25), Zim Laboratories Ltd achieved a total income of ₹119.40 crores. This figure represents a significant quarter-over-quarter (QoQ) increase of 21.7% compared to ₹98.08 crores in the third quarter of fiscal year 2025 (Q3FY25). Year-over-year (YoY), there is a 12.5% increase from the total income of ₹106.10 crores recorded in the fourth quarter of fiscal year 2024 (Q4FY24). The marked growth in total income both QoQ and YoY reflects the company's operational performance during this period.
Profitability
For Q4FY25, Zim Laboratories Ltd reported a Profit Before Tax (PBT) of ₹11.00 crores, marking a substantial QoQ growth of 93.0% from ₹5.70 crores in Q3FY25, and a YoY increase of 10.7% from ₹9.94 crores in Q4FY24. The tax expenses for Q4FY25 amounted to ₹2.91 crores, which is a 71.2% increase QoQ from ₹1.70 crores in Q3FY25 and a 7.4% increase YoY from ₹2.71 crores in Q4FY24. Consequently, the Profit After Tax (PAT) for Q4FY25 stood at ₹8.09 crores, reflecting a robust QoQ increase of 102.3% from ₹4.00 crores in Q3FY25 and an 11.7% YoY rise from ₹7.24 crores in Q4FY24. The Earnings Per Share (EPS) for Q4FY25 was ₹1.70, up by 112.5% QoQ from ₹0.80 in Q3FY25 and by 13.3% YoY from ₹1.50 in Q4FY24.
Operating Metrics
The total expenses for Zim Laboratories Ltd in Q4FY25 were recorded at ₹108.41 crores, which is a 17.4% increase QoQ from ₹92.38 crores in Q3FY25, and a 12.7% increase YoY from ₹96.16 crores in Q4FY24. This data indicates that while the company's expenses have risen, they are in line with the growth in total income and profitability metrics. The increase in expenses, alongside the growth in revenue and profits, suggests an expansion in operational activities. Further detailed financial ratios such as the P/E ratio, debt-to-equity ratio, or current ratio are not provided in the available data.